MENLO PARK, Calif.,
July 13, 2017 /PRNewswire/ --
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical
company focusing on dermatology, will present results of its phase
2b research of BPX-01, a unique topical hydrophilic gel formulation
of minocycline, at the Dermatology Education Foundation's Essential
Resource Meeting, DERM 2017, being held July 20-23 in Las
Vegas. e data, to be shared in a poster entitled "Safety,
Efficacy and Patient Satisfaction of BPX-01 2% Minocycline Topical
Gel for Acne Vulgaris," will show the 2% formulation of BPX-01
reduced acne lesions in phase 2b subjects by 59% (compared to 44%
for vehicle) and delivered at least a two-grade reduction in
investigator global assessment (IGA) and clear to almost clear for
25% of subjects. The study also found BPX-01 was generally well
tolerated, without any serious drug-related adverse events
experienced, photosensitivity, staining or skin discoloration.
![(PRNewsfoto/BioPharmX Corporation) (PRNewsfoto/BioPharmX Corporation)](https://mma.prnewswire.com/media/510652/BioPharmX_Corporation_Logo.jpg)
A survey of study participants showed that 86% would use BPX-01
again and 79% said it was easy to use and apply the drug.
"The high efficacy rate and good tolerability scores suggest
that the novel BPX-01 may be a promising treatment for acne, a skin
condition that has not benefited from innovative new therapies for
many decades," said Hilary Baldwin,
M.D., board-certified dermatologist and Medical Director of The
Acne Treatment and Research Center, Morristown, NJ. "We are
particularly enthusiastic that patients told us they would use
BPX-01 again, since a serious impediment to effective acne care
today is that patients often fail to use their prescribed acne
medications consistently, often because they are associated with
undesirable side effects. BPX-01 presented no such side
effects."
BPX-01 data will also be discussed by prominent dermatology
thought leaders during two podium presentations at the national
dermatology meeting on July 21:
- "Acne and Rosacea: New Therapeutic Agents," a
presentation by Drs. Linda Stein
Gold and Hilary Baldwin, at
1:15 p.m.
- "Poster Highlights Discussion," led by Joe Gorelick and Dr. Julie Harper, at 4:30
p.m.
BPX-01 is the first topical gel formulation of minocycline that
can penetrate the skin to deliver the antibiotic to the the
pilosebaceous unit, where acne-associated bacterium, P.
acnes resides. It is also the first and only stable hydrophilic
and non-oil-based topical gel with fully solubilized minocycline.
The company's studies are designed to confirm whether BPX-01 will
effectively treat acne with lower dosages of the antibiotic with no
or fewer adverse side effects.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting up to 50 million
Americans. The disease can cause permanent scarring, low
self-esteem, depression and anxiety.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
safety and medical effects of BPX-01, the effect BPX-01 may have on
the treatment of acne, the commencement and results of future
trials of BPX-01 and the size of such trials, continued and
consistent results in future tests of BPX-01 and absence of side
effects of future use of BPX-01. These forward-looking statements
may be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017 and quarterly report on Form 10-Q for the
period ended April 30, 2017. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof, and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-phase-2b-clinical-trial-data-at-national-def-essential-resource-meeting-2017-300487673.html
SOURCE BioPharmX Corporation